Wockhardt and its subsidiaries Wockhardt UK Holdings and CP Pharmaceuticals have settled an ongoing litigation with Teva Pharmaceuticals, US, in the High Court of London. The litigation, relating to the supply contract for Trisenox, is over the price charged by CP Pharmaceuticals. The Wockhardt firms have agreed to waive their claim for outstanding trade receivables worth €20 million and further paid €23 million to Teva and Cephalon (its affiliate) for a final settlement.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.